Trials / Completed
CompletedNCT06756620
Investigation of the Etiology of Hypertension and Endothelial Damage in Patients With Cytochrome P450 Oxidoreductase Deficiency
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 51 (actual)
- Sponsor
- Ozge Bayrak Demirel · Academic / Other
- Sex
- All
- Age
- 7 Years
- Healthy volunteers
- Accepted
Summary
This study investigates the etiology of hypertension and endothelial damage in patients with Cytochrome P450 Oxidoreductase (POR) deficiency. The study involves comparing ambulatory blood pressure monitoring (ABPM), endothelial biomarkers (Prostaglandin E2, Thromboxane B2, and Nitric Oxide levels), and capillaroscopy findings between POR deficiency patients and healthy controls.
Detailed description
Cytochrome P450 Oxidoreductase (POR) deficiency is a rare autosomal recessive condition associated with congenital adrenal hyperplasia and other systemic complications. This study aims to elucidate the role of endothelial dysfunction and hypertension in POR deficiency by comparing the biochemical, vascular, and clinical parameters of POR-deficient patients with age- and gender-matched healthy controls. The research could pave the way for targeted therapeutic interventions.
Conditions
- Cytochrome P450 Oxidoreductase Deficiency
- Hypertension
- Endothelial Dysfunction
- Congenital Adrenal Hyperplasia
Timeline
- Start date
- 2024-12-24
- Primary completion
- 2025-08-12
- Completion
- 2025-08-12
- First posted
- 2025-01-03
- Last updated
- 2025-09-08
Locations
1 site across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT06756620. Inclusion in this directory is not an endorsement.